Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekt af 10 mg Xanamem på demens på grund af Alzheimers sygdom (XanaMIA)

19. oktober 2026 opdateret af: Actinogen Medical

Et fase 2b, dobbeltblindt, placebokontrolleret, parallelle grupper, 36 ugers, 2-arms forsøg for at vurdere sikkerheden, tolerabiliteten og effektiviteten af ​​Xanamem® 10 mg dagligt hos patienter med mild eller moderat demens på grund af Alzheimers sygdom

Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).

This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

247

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New South Wales
      • Darlinghurst, New South Wales, Australien
        • ACW Investigative Site 106
      • Erina, New South Wales, Australien
        • ACW Investigative Site 103
      • Kogarah, New South Wales, Australien
        • ACW Investigative Site 102
      • Macquarie Park, New South Wales, Australien
        • ACW Investigative Site 107
      • Newcastle, New South Wales, Australien
        • ACW Investigative Site 111
    • Queensland
      • Birtinya, Queensland, Australien
        • ACW Investigative Site 113
      • Chermside, Queensland, Australien
        • ACW Investigative Site 105
    • South Australia
      • Bedford Park, South Australia, Australien
        • ACW Investigative Site 114
      • Woodville South, South Australia, Australien
        • ACW Investigative Site 110
    • Victoria
      • Carlton, Victoria, Australien
        • ACW Investigative Site 115
      • Ivanhoe, Victoria, Australien
        • ACW Investigative Site 101
      • Malvern, Victoria, Australien
        • ACW Investigative Site 108
      • Parkville, Victoria, Australien
        • ACW Investigative Site 112
    • Western Australia
      • Nedlands, Western Australia, Australien
        • ACW Investigative Site 104
      • West Perth, Western Australia, Australien
        • ACW Investigative Site 109
    • California
      • Carlsbad, California, Forenede Stater, 92011
        • ACW Investigative Site 218
      • Sherman Oaks, California, Forenede Stater, 91403
        • ACW Investigative Site 209
    • Colorado
      • Denver, Colorado, Forenede Stater, 80218
        • ACW Investigative Site 211
      • Englewood, Colorado, Forenede Stater, 80113
        • ACW Investigative Site 208
    • Florida
      • Delray Beach, Florida, Forenede Stater, 33445
        • ACW Investigative Site 203
      • Miami, Florida, Forenede Stater, 33176
        • ACW Investigative site 201
      • New Port Richey, Florida, Forenede Stater, 34652
        • ACW Investigative site 202
      • Orlando, Florida, Forenede Stater, 32803
        • ACW Investigative site 204
      • The Villages, Florida, Forenede Stater, 32162
        • ACW Investigative site 205
    • Georgia
      • Decatur, Georgia, Forenede Stater, 30030
        • ACW Investigative Site 207
    • New Jersey
      • Marlton, New Jersey, Forenede Stater, 08053
        • ACW Investigative Site 206
    • New York
      • Albany, New York, Forenede Stater, 12208
        • ACW Investigative Site 214
      • Staten Island, New York, Forenede Stater, 10314
        • ACW Investigative Site 219
    • Ohio
      • Dayton, Ohio, Forenede Stater, 45459
        • ACW Investigative Site 210
      • Independence, Ohio, Forenede Stater, 44131
        • ACW Investigative Site 217
    • Oregon
      • Portland, Oregon, Forenede Stater, 97225
        • ACW Investigative Site 212
    • Rhode Island
      • East Providence, Rhode Island, Forenede Stater, 02914
        • ACW Investigative Site 216
    • Texas
      • Austin, Texas, Forenede Stater, 78757
        • ACW Investigative Site 220
    • Washington
      • Bellevue, Washington, Forenede Stater, 98007
        • ACW Investigative Site 215

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female aged 50 years or older, inclusive at the time of Screening.

  • Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria:

    1. Clinical Dementia Rating (CDR) global score of 0.5 to 1.0
    2. Mini-mental state examination (MMSE) score of 18 to 26
    3. Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings
    4. Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein.
  • If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening.

  • Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion.

  • Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.

  • Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments.

  • Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.

Exclusion Criteria:

  • Use of anti-amyloid or anti-tau antibody within 6 months.
  • Diagnosis of a non-AD dementia including traumatic brain injury.
  • Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia.
  • Participation in another clinical trial of a drug or device
  • Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator.
  • Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening.
  • Clinical diagnosis of Type I or Type II diabetes requiring insulin.
  • Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C.
  • Participants with a history of clinically significant drug abuse or addiction in the past 2 years
  • Evidence or history of alcohol abuse

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: 10 mg Xanamem

10 mg Xanamem tablet, to be administered orally once every morning with or without food

Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.

Andre navne:
  • UE2343
Placebo komparator: Placebo

Placebo tablet, to be administered orally once every morning with or without food

Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.

Eksperimentel: Open label phase

Participants enrolled in the open-label phase after the main trial will receive 10 mg Xanamem, to be administered orally once every morning with or without food

Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.

Andre navne:
  • UE2343

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Effects of 10 mg Xanamem on integrated cognitive and functional abilities
Tidsramme: 36 weeks

Change from Baseline to end of treatment (EOT) in the Clinical Dementia Ratio - Sum of Boxes (CDR-SB). The CDR-SB is calculated as an average score, with lower scores indicating improvement.

36 weeks
Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]
Tidsramme: 36 weeks

Incidence and severity of TEAEs

36 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Global Program Lead, Actinogen Medical Ltd

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

12. april 2024

Primær færdiggørelse (Faktiske)

22. september 2026

Studieafslutning (Anslået)

1. februar 2028

Datoer for studieregistrering

Først indsendt

23. oktober 2023

Først indsendt, der opfyldte QC-kriterier

5. november 2023

Først opslået (Faktiske)

9. november 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

19. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ACW0009

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .